Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study

Int J Infect Dis. 2024 May:142:106990. doi: 10.1016/j.ijid.2024.106990. Epub 2024 Feb 28.

Abstract

Background: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease.

Methods: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4-G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition.

Results: Two hundred sixteen CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17-1.78)], P < 0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per 10-fold increase in antibody level after vaccination (aOR 0.82 [0.70-0.96], P = 0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61-8.25], P = 0.003).

Conclusions: CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19.

Keywords: Chronic kidney disease; Dialysis; Kidney transplant recipient; Long-COVID; Post COVID-19 condition; Solid organ transplant recipient; immunocompromised.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • Case-Control Studies
  • Chronic Disease
  • Humans
  • Prospective Studies
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / epidemiology
  • Renal Insufficiency, Chronic* / therapy
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines